Company intelligence / Profile preview

Endacea Diagnostics

Research Triangle Park / Raleigh area, North Carolina, United Statesendacea.org ↗

Ownership: Private
Development stage: Other

Overview

Endacea Diagnostics is a subsidiary of Endacea focused on developing and commercializing a proprietary endotoxin assay intended to sensitively and specifically detect patients with or at risk of sepsis. The parent company's lead compound L‑97‑1 is in late preclinical development as an intravenous anti-sepsis drug candidate. No clinical results have been published yet for the diagnostic.

Therapeutic areas: NephrologyImmunologyPulmonologyInfectious Diseases
Modalities: Diagnostic assaySmall molecule
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Endacea Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endacea Diagnostics.

Explore the full profile